Search

everythinglearnresearchcommunity

for

Search:↓

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.

Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Mitf plays a key role in melanoma progression and is linked to disease stage.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Immunotherapies for non-small cell lung cancer show promise in improving treatment and reducing side effects.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

Two microRNAs in stem cell exosomes help treat hair loss by targeting a specific signaling pathway.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Entospletinib effectively prevents eye and skin GVHD in mice.

MITF+ melanoma patients are more likely to have multiple melanomas and unique skin patterns.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

AMPK activation may reduce melanoma risk in red-haired individuals.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.